Overview

Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease

Status:
Withdrawn

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of MLN1202 on arterial inflammation in participants with stable atherosclerotic cardiovascular disease (CVD) who are receiving standard-of-care (SOC) therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

Antibodies, Monoclonal